The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years because of Washington's insistence on sensitive data.
This move was revealed following a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesman has since explained that the US was seeking genetic material for research and commercial purposes while was unwilling to guarantee the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further negotiations to find a deal acceptable to both sides so the country's critical HIV treatment initiative can continue.
Broader Background
This rejection comes after a comparable situation in neighbouring Kenya, where a court blocked a similar health funding agreement following concerns were filed about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government deals to boost openness and accountability.
According to statements, 16 African countries have to date agreed to similar health pacts, constituting over $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information for a long time, without any corresponding assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our country would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our people if a new pandemic emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending structures previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This system is designed to ensure that when a country contributes its data, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued discussions with our US partners on how subsequent co-operation could be designed in a manner that honours the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it acknowledged the government's concerns, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives were funded by external financing.
"If specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," it said.
The situation highlights the ongoing tensions between accepting vital international aid and protecting local interests in an ever more data-driven world.